The drug Kaftrio and a new therapeutic indication for the drug Orkambi have been approved for use in National Health Service hospitals in the treatment of cystic fibrosis, announced Infarmed.
In a statement, the National Authority for Medicines and Health Products explains that the drug Kaftrio has been approved for use, in a certain therapeutic regimen, in patients aged 12 years and over.
This drug became known in Portugal after the appeal for its approval launched by the young Constança Bradell, who suffered from cystic fibrosis and died on July 11, at the age of 24. At the time, the young woman received a special authorization from Infarmed after an emotional appeal on social networks.
As for the drug Orkambi, it is approved for the treatment of cystic fibrosis in children aged between two and 11 years.
“The financing for the use of these drugs in the National Health Service is governed by a contract between the company that owns the drug and INFARMED – National Authority for Medicines and Health Products, IP, authorized by the Secretary of State for Health”, the note adds. .
Until now, there were in Portugal three approved modulator drugs for cystic fibrosis, a chronic, hereditary disease caused by alterations in the CFTR gene.